| abstract |
The present invention provides a protein kinase degradant and use thereof. Specifically, the present invention provides a compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can perform ubiquitination and degradation on AXL, FLT3, AURORA-A, AURORA-B, B-RAF, A-RAF, MET, LCK, MEK2, and other proteins in a targeted mode, and thus can be used for the treatment of indications related to abnormal expression of proteins such as AXL, FLT3, AURORA-A, AURORA-B, B-RAF, A-RAF, MET, LCK, and MEK2. |